Log in

NASDAQ:CDXS - Codexis Stock Price, Forecast & News

$12.95
-0.56 (-4.15 %)
(As of 02/26/2020 09:08 AM ET)
Today's Range
$12.89
Now: $12.95
$13.59
50-Day Range
$12.95
MA: $16.10
$18.60
52-Week Range
$12.68
Now: $12.95
$22.38
Volume313,306 shs
Average Volume330,274 shs
Market Capitalization$757.83 million
P/E RatioN/A
Dividend YieldN/A
Beta0.28
Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. Read More…

Industry, Sector and Symbol

Industry Industrial organic chemicals
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CDXS
CUSIP19200510
Phone650-421-8100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$60.59 million
Book Value$1.04 per share

Profitability

Net Income$-10,880,000.00

Miscellaneous

Employees132
Market Cap$757.83 million
Next Earnings Date2/27/2020 (Confirmed)
OptionableOptionable

Receive CDXS News and Ratings via Email

Sign-up to receive the latest news and ratings for CDXS and its competitors with MarketBeat's FREE daily newsletter.


Codexis (NASDAQ:CDXS) Frequently Asked Questions

What is Codexis' stock symbol?

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

How were Codexis' earnings last quarter?

Codexis, Inc. (NASDAQ:CDXS) released its quarterly earnings data on Tuesday, November, 5th. The biotechnology company reported $0.01 earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.09) by $0.10. The biotechnology company had revenue of $21.91 million for the quarter, compared to analysts' expectations of $16.56 million. Codexis had a negative net margin of 17.85% and a negative return on equity of 15.24%. View Codexis' Earnings History.

When is Codexis' next earnings date?

Codexis is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Codexis.

How can I listen to Codexis' earnings call?

Codexis will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for CDXS?

2 equities research analysts have issued twelve-month price objectives for Codexis' shares. Their forecasts range from $22.50 to $25.00. On average, they expect Codexis' stock price to reach $23.75 in the next twelve months. This suggests a possible upside of 83.4% from the stock's current price. View Analyst Price Targets for Codexis.

What is the consensus analysts' recommendation for Codexis?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Codexis.

Has Codexis been receiving favorable news coverage?

News stories about CDXS stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Codexis earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the next several days. View News Stories for Codexis.

Are investors shorting Codexis?

Codexis saw a increase in short interest in January. As of January 31st, there was short interest totalling 5,410,000 shares, an increase of 8.4% from the January 15th total of 4,990,000 shares. Based on an average daily trading volume, of 335,000 shares, the short-interest ratio is currently 16.1 days. Approximately 10.1% of the company's stock are short sold. View Codexis' Current Options Chain.

Who are some of Codexis' key competitors?

What other stocks do shareholders of Codexis own?

Who are Codexis' key executives?

Codexis' management team includes the folowing people:
  • Mr. John J. Nicols, Pres, CEO & Director (Age 55)
  • Mr. Gordon T. B. Sangster, Sr. VP & CFO (Age 66)
  • Dr. James J. Lalonde, Sr. VP of R&D (Age 58)
  • Ms. Laurie Heilmann, Sr. VP of Bus. Devel. & Marketing
  • Prof. Gerhard N. Mayr, Special Advisor to the Board (Age 73)

Who are Codexis' major shareholders?

Codexis' stock is owned by many different of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (6.47%), William Blair Investment Management LLC (2.96%), Janus Henderson Group PLC (2.57%), Nikko Asset Management Americas Inc. (2.35%), Sumitomo Mitsui Trust Holdings Inc. (2.35%) and FMR LLC (2.33%). Company insiders that own Codexis stock include Bernard J Kelley, Byron L Dorgan, David V Smith, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Kathleen Sereda Glaub, Michael D Aldridge, Pam P Cheng, Patrick Y Yang and Thomas R Baruch. View Institutional Ownership Trends for Codexis.

Which major investors are selling Codexis stock?

CDXS stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Prescott Group Capital Management L.L.C., FMR LLC, Oak Ridge Investments LLC, Stifel Financial Corp, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc. and Bank of America Corp DE. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols and Thomas R Baruch. View Insider Buying and Selling for Codexis.

Which major investors are buying Codexis stock?

CDXS stock was bought by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Baillie Gifford & Co., Janus Henderson Group PLC, Aviva PLC, Essex Investment Management Co. LLC, Goldman Sachs Group Inc., Barclays PLC and Marshall Wace LLP. Company insiders that have bought Codexis stock in the last two years include John J Nicols and Patrick Y Yang. View Insider Buying and Selling for Codexis.

How do I buy shares of Codexis?

Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Codexis' stock price today?

One share of CDXS stock can currently be purchased for approximately $12.95.

How big of a company is Codexis?

Codexis has a market capitalization of $757.83 million and generates $60.59 million in revenue each year. The biotechnology company earns $-10,880,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Codexis employs 132 workers across the globe.View Additional Information About Codexis.

What is Codexis' official website?

The official website for Codexis is http://www.codexis.com/.

How can I contact Codexis?

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at 650-421-8100 or via email at [email protected]


MarketBeat Community Rating for Codexis (NASDAQ CDXS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  304 (Vote Outperform)
Underperform Votes:  312 (Vote Underperform)
Total Votes:  616
MarketBeat's community ratings are surveys of what our community members think about Codexis and other stocks. Vote "Outperform" if you believe CDXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Featured Article: What Are Cryptocurrencies?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel